Invivyd FY revenue rises; operating expenses cut sharply

Reuters03-05
Invivyd FY revenue rises; operating expenses cut sharply

Overview

  • Biopharmaceutical company reported Q4 PEMGARDA net product revenue up 25% yr/yr

  • Loss per share for 2025 beat analyst expectations

  • Net loss for 2025 beat analyst estimates

Outlook

  • Invivyd expects top-line data from DECLARATION trial mid-2026

  • Company anticipates advancing RSV candidate VBY329 toward IND readiness in 2H 2026

  • Invivyd's cash reserves are expected to support DECLARATION trial and pipeline programs

Result Drivers

  • PEMGARDA REVENUE GROWTH - Q4 PEMGARDA revenue increased 25% yr/yr and 31% qtr/qtr, driven by commercial execution and appeal for monoclonal antibody prophylaxis

  • OPERATING EXPENSES REDUCED - Operating expenses were reduced by nearly half, demonstrating financial discipline

Company press release: ID:nGNX8b1R3F

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

FY Revenue

$53.43 mln

FY EPS

Beat

-$0.30

-$0.39 (4 Analysts)

FY Net Income

Beat

-$52.49 mln

-$57.82 mln (4 Analysts)

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Invivyd Inc is $10.00, about 484.8% above its March 4 closing price of $1.71

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment